Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study (Q38390490)
Jump to navigation
Jump to search
scientific article published on 05 July 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study |
scientific article published on 05 July 2016 |
Statements
1 reference
Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study (English)
1 reference
Tjalf Ziemssen
1 reference
Hans-Peter Hartung
1 reference
Olaf Stüve
1 reference
Ludwig Kappos
1 reference
Krzysztof Selmaj
1 reference
Xavier Montalban
1 reference
Mark S Freedman
1 reference
Bernhard Hemmer
1 reference
Peter Rieckmann
1 reference
Erik Wallström
1 reference
David K B Li
1 reference
Brian Hunter
1 reference
Sophie Arnould
1 reference
5 July 2016
1 reference
1 reference
73
1 reference
9
1 reference
1089-1098
1 reference
Identifiers
1 reference
1 reference